Genocea Biosciences Inc. (NASDAQ:GNCA)‘s stock had its “buy” rating reissued by investment analysts at FBR & Co in a research report issued on Wednesday. They presently have a $17.00 price objective on the stock. FBR & Co’s target price would suggest a potential upside of 303.80% from the company’s previous close.
Several other brokerages have also weighed in on GNCA. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price objective on shares of Genocea Biosciences in a report on Thursday, September 29th. Piper Jaffray Cos. lowered their price objective on Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, September 29th. Finally, Zacks Investment Research lowered Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, July 6th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Genocea Biosciences currently has an average rating of “Buy” and a consensus price target of $16.96.
Shares of Genocea Biosciences (NASDAQ:GNCA) opened at 4.19 on Wednesday. Genocea Biosciences has a 12 month low of $2.56 and a 12 month high of $8.20. The firm’s market capitalization is $118.72 million. The company has a 50 day moving average price of $5.29 and a 200-day moving average price of $4.72.
Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.39) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.44) by $0.05. Genocea Biosciences had a negative return on equity of 47.87% and a negative net margin of 5,121.17%. Equities research analysts expect that Genocea Biosciences will post ($1.63) EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in GNCA. Geode Capital Management LLC increased its stake in Genocea Biosciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 136,990 shares of the company’s stock worth $1,060,000 after buying an additional 1,743 shares during the period. AXA increased its stake in shares of Genocea Biosciences by 1.4% in the second quarter. AXA now owns 595,157 shares of the company’s stock worth $2,440,000 after buying an additional 8,183 shares during the period. FMR LLC increased its stake in shares of Genocea Biosciences by 0.5% in the second quarter. FMR LLC now owns 4,244,037 shares of the company’s stock worth $17,401,000 after buying an additional 21,149 shares during the period. Alpine Partners VI LLC bought a new stake in shares of Genocea Biosciences during the second quarter worth approximately $120,000. Finally, State Street Corp increased its stake in shares of Genocea Biosciences by 11.9% in the first quarter. State Street Corp now owns 291,020 shares of the company’s stock worth $2,256,000 after buying an additional 30,920 shares during the period. Hedge funds and other institutional investors own 56.49% of the company’s stock.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.